A pair of Sage Therapeutics veterans has launched a neurology-focused startup armed with $106 million and a clinical-stage ...

Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person syndrome (SPS), ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution ...

Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis (RMS) trials, revealing that deaths from ...

Pulnovo Medical, a Chinese medtech focused on therapies that target pulmonary hypertension and heart failure, hauled in ...

With a few chemical tweaks and some dutiful protein partners, a new biotech from Flagship Pioneering thinks it has cracked ...

Gene therapy biotech Ray Therapeutics has announced the closing of a $125 million series B financing to support the company’s ...

Replimune is saying goodbye to a further 161 employees across two Massachusetts sites as the company continues to reel from ...

Roche’s Foundation Medicine is deepening its longstanding ties with Bristol Myers Squibb as the companies team up on a new ...

Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another trial—leading Gilead to pull further away from their once wide-ranging | ...

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia ...

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building ...